Skip to content

US · SI · MEDICAL - SPECIALTIES

Shoulder Innovations, Inc. (SI) intrinsic value and stock valuation

$20.15as of 2026-11-21 · Mkt cap 427M

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Shoulder Innovations, Inc. DCF and intrinsic value

InvestorsCraft values SI with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from SI’s statements →

Shoulder Innovations, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Specialties Grand Rapids, MI 92037 shoulderinnovations.com

How the business is doing

Fiscal 2023–2025, USD

Revenue
$47.3M
20232025
Net income
-$-40.36M
20232025
Free cash flow
-$-36.02M
20232025
Total equity
$154.9M
20232025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2023–2025, USD
202520242023
Revenue$47.3M$31.6M$19.3M
Operating income-$-26.3M-$-14.65M-$-10.86M
Net income-$-40.36M-$-15.62M-$-12.65M
EPSd-$-1.96M-$-784.14K-$-635.04K
Operating cash flow-$-28.61M-$-14.14M-$-13.14M
Capital expenditure-$-7.41M-$-4.01M-$-2.75M
Free cash flow-$-36.02M-$-18.16M-$-15.89M
Total assets$169.9M$43.1M$54.3M
Total debt$15M$14.7M$14.5M
Net debt-$-11.85M$8.61M$8.23M
Total equity$154.9M-$-54.7M-$-39.74M
Cash and short-term investments$124.3M$15M$32.8M
Income statement
202520242023
Revenue$47.3M$31.6M$19.3M
Cost of revenue$11.1M$7.28M$4M
Gross profit$36.2M$24.3M$15.3M
Research and development expenses$7.73M$4.49M$3.02M
Selling, general and administrative expenses$54.8M$34.5M$23.1M
Other expenses$0.00$0.00$0.00
Operating expenses$62.5M$39M$26.1M
Cost and expenses$73.6M$46.3M$30.1M
Interest income$0.00$0.00$0.00
Interest expense$70K$1.32M$760K
Depreciation and amortization$3.21M$2.2M$1.64M
Ebitda-$-37.08M-$-12.11M-$-10.25M
Operating income-$-26.3M-$-14.65M-$-10.86M
Total other income/expenses, net-$-14.06M-$-970K-$-1.79M
Income before tax-$-40.36M-$-15.62M-$-12.65M
Income tax expense$0.00$0.00$0.00
Net income-$-40.36M-$-15.62M-$-12.65M
Weighted average shares outstanding$20.6M$19.9M$19.9M
Weighted average diluted shares outstanding$20.6M$19.9M$19.9M
Balance sheet
202520242023
Cash and short-term investments$124.3M$15M$32.8M
Net receivables$8.27M$5.12M$4.69M
Inventory$21.6M$14M$9.92M
Total current assets$157.2M$35.1M$47.9M
Property, plant and equipment, net$12.6M$7.55M$5.75M
Goodwill and intangible assets$100K$400K$700K
Long-term investments$0.00$0.00$0.00
Total non-current assets$12.7M$7.96M$6.45M
Total assets$169.9M$43.1M$54.3M
Accounts payable$0.00$4.86M$1.96M
Short-term debt$60K$90K$90K
Deferred revenue$0.00$0.00$0.00
Total current liabilities-$-7.77M$7.65M$4.28M
Long-term debt$15M$14.7M$14.4M
Deferred revenue, non-current$0.00$0.00$0.00
Total non-current liabilities$15M$90.1M$89.8M
Capital lease obligations$0.00$70K$110K
Total liabilities$15M$97.8M$94M
Common stock$20.6B$0.00$0.00
Retained earnings$0.00-$-57.04M-$-41.42M
Accumulated other comprehensive income (loss)$0.00$200K$360K
Total equity$154.9M-$-54.7M-$-39.74M
Total investments$80K$8.92M$26.6M
Total debt$15M$14.7M$14.5M
Net debt-$-11.85M$8.61M$8.23M
Cash flow statement
202520242023
Net income-$-40.36M-$-15.62M-$-12.65M
Depreciation and amortization$3.21M$2.2M$1.64M
Stock-based compensation$1M$750K$450K
Change in working capital-$-6.75M-$-1.04M-$-4.76M
Accounts receivable-$-3.3M-$-570K-$-2.69M
Inventory-$-7.64M-$-4.03M-$-2.41M
Accounts payable$3.37M$3.12M-$-740K
Net cash provided by operating activities-$-28.61M-$-14.14M-$-13.14M
Investments in property, plant and equipment-$-7.41M-$-4.01M-$-2.75M
Acquisitions, net$0.00$0.00$0.00
Net cash used for investing activities-$-95.6M$14M-$-28.97M
Common stock issued$39.5M$70K$34.9M
Common stock repurchased$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00
Net cash used for financing activities$145M$70K$44.7M
Net change in cash$20.8M-$-110K$2.61M
Cash at end of period$26.9M$6.12M$6.24M
Operating cash flow-$-28.61M-$-14.14M-$-13.14M
Capital expenditure-$-7.41M-$-4.01M-$-2.75M
Free cash flow-$-36.02M-$-18.16M-$-15.89M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Shoulder Innovations, Inc.

        Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI.

        CEO
        Robert Joseph Ball
        Employees
        75
        Beta
        -1.70

        Explore

        Frequently asked questions

        What is the intrinsic value of Shoulder Innovations, Inc. (SI)?

        Shoulder Innovations, Inc. (SI) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is SI undervalued?

        SI trades at a price of $20.15 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.